Literature DB >> 22043968

ADHD drugs and serious cardiovascular events in children and young adults.

William O Cooper1, Laurel A Habel, Colin M Sox, K Arnold Chan, Patrick G Arbogast, T Craig Cheetham, Katherine T Murray, Virginia P Quinn, C Michael Stein, S Todd Callahan, Bruce H Fireman, Frank A Fish, Howard S Kirshner, Anne O'Duffy, Frederick A Connell, Wayne A Ray.   

Abstract

BACKGROUND: Adverse-event reports from North America have raised concern that the use of drugs for attention deficit-hyperactivity disorder (ADHD) increases the risk of serious cardiovascular events.
METHODS: We conducted a retrospective cohort study with automated data from four health plans (Tennessee Medicaid, Washington State Medicaid, Kaiser Permanente California, and OptumInsight Epidemiology), with 1,200,438 children and young adults between the ages of 2 and 24 years and 2,579,104 person-years of follow-up, including 373,667 person-years of current use of ADHD drugs. We identified serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) from health-plan data and vital records, with end points validated by medical-record review. We estimated the relative risk of end points among current users, as compared with nonusers, with hazard ratios from Cox regression models.
RESULTS: Cohort members had 81 serious cardiovascular events (3.1 per 100,000 person-years). Current users of ADHD drugs were not at increased risk for serious cardiovascular events (adjusted hazard ratio, 0.75; 95% confidence interval [CI], 0.31 to 1.85). Risk was not increased for any of the individual end points, or for current users as compared with former users (adjusted hazard ratio, 0.70; 95% CI, 0.29 to 1.72). Alternative analyses addressing several study assumptions also showed no significant association between the use of an ADHD drug and the risk of a study end point.
CONCLUSIONS: This large study showed no evidence that current use of an ADHD drug was associated with an increased risk of serious cardiovascular events, although the upper limit of the 95% confidence interval indicated that a doubling of the risk could not be ruled out. However, the absolute magnitude of such an increased risk would be low. (Funded by the Agency for Healthcare Research and Quality and the Food and Drug Administration.).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22043968      PMCID: PMC4943074          DOI: 10.1056/NEJMoa1110212

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  38 in total

Review 1.  Treatment of attention-deficit-hyperactivity disorder.

Authors:  J Elia; P J Ambrosini; J L Rapoport
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

2.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

3.  International diagnostic criteria for acute myocardial infarction and acute stroke.

Authors:  R F Gillum; S P Fortmann; R J Prineas; T E Kottke
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

Review 4.  Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.

Authors:  Ronald T Brown; Robert W Amler; Wendy S Freeman; James M Perrin; Martin T Stein; Heidi M Feldman; Karen Pierce; Mark L Wolraich
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

5.  Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.

Authors:  Wayne A Ray; Katherine T Murray; Marie R Griffin; Cecilia P Chung; Walter E Smalley; Kathi Hall; James R Daugherty; Lisa A Kaltenbach; C Michael Stein
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

6.  Diuretic therapy for hypertension and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; B M Psaty; T D Koepsell; K G Wicklund; X Lin; L Cobb; P M Rautaharju; M K Copass; E H Wagner
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

7.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

8.  An algorithm to identify incident myocardial infarction using Medicaid data.

Authors:  Neesha N Choma; Marie R Griffin; Robert L Huang; Edward F Mitchel; Lisa A Kaltenbach; Patricia Gideon; Shannon M Stratton; Christianne L Roumie
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-11       Impact factor: 2.890

9.  Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

Authors:  Suzanne McCarthy; Noel Cranswick; Laura Potts; Eric Taylor; Ian C K Wong
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Recall accuracy for prescription medications: self-report compared with database information.

Authors:  S L West; D A Savitz; G Koch; B L Strom; H A Guess; A Hartzema
Journal:  Am J Epidemiol       Date:  1995-11-15       Impact factor: 4.897

View more
  111 in total

1.  ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Authors:  Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby
Journal:  JAMA       Date:  2011-12-12       Impact factor: 56.272

2.  Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.

Authors:  Craig F Garfield; E Ray Dorsey; Shu Zhu; Haiden A Huskamp; Rena Conti; Stacie B Dusetzina; Ashley Higashi; James M Perrin; Rachel Kornfield; G Caleb Alexander
Journal:  Acad Pediatr       Date:  2012-02-10       Impact factor: 3.107

Review 3.  Management of depression after myocardial infarction.

Authors:  Peter A Shapiro
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

4.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

Review 5.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

6.  Use of Unsolicited Patient Observations to Identify Surgeons With Increased Risk for Postoperative Complications.

Authors:  William O Cooper; Oscar Guillamondegui; O Joe Hines; C Scott Hultman; Rachel R Kelz; Perry Shen; David A Spain; John F Sweeney; Ilene N Moore; Joseph Hopkins; Ira R Horowitz; Russell M Howerton; J Wayne Meredith; Nathan O Spell; Patricia Sullivan; Henry J Domenico; James W Pichert; Thomas F Catron; Lynn E Webb; Roger R Dmochowski; Jan Karrass; Gerald B Hickson
Journal:  JAMA Surg       Date:  2017-06-01       Impact factor: 14.766

7.  Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.

Authors:  Søren Dalsgaard; Anette Primdal Kvist; James F Leckman; Helena Skyt Nielsen; Marianne Simonsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-06-23       Impact factor: 2.576

8.  The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial.

Authors:  Ludger Tebartz van Elst; Simon Maier; Stefan Klöppel; Erika Graf; Carola Killius; Marthe Rump; Esther Sobanski; Dieter Ebert; Mathias Berger; Andreas Warnke; Swantje Matthies; Evgeniy Perlov; Alexandra Philipsen
Journal:  J Psychiatry Neurosci       Date:  2016-10       Impact factor: 6.186

Review 9.  Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis.

Authors:  Hui Liu; Wenjing Feng; Dongfeng Zhang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-08-24       Impact factor: 4.785

Review 10.  Sudden Cardiac Death in the Young.

Authors:  Michael Ackerman; Dianne L Atkins; John K Triedman
Journal:  Circulation       Date:  2016-03-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.